Presence of HIV-1 RNA between 102 and 104 copies/ml correlated with quantity of Tier 2 viruses neutralized when compared with those 102 (p .0001) and trended toward significance when compared with those with 104 copies/ml (p=.076). in those with HIV-1 RNA between 100 and 10,000 copies/ml compared to those 100 or 10,000 copies/ml (p=.0003 and .0245, respectively). Individuals with HIV-1 RNA 100C10,000 copies/ml experienced a higher quantity of Tier 2 viruses neutralized compared to Rolipram the 100or 10,000 copies/ml organizations (p= .0001 Rolipram and p=.076, respectively). Male sex was associated with broad HIV-1 neutralizing antibody activity (p=.016). Summary These results show that low but prolonged HIV antigen manifestation correlates with broad HIV-1 neutralizing antibody activity. At higher levels of plasma viremia, neutralization titers were diminished. Conversely, at lower levels, there appears to be insufficient antigen activation to keep up high neutralization titers. These findings may have important implications in furthering the understanding of the humoral response to HIV illness. strong class=”kwd-title” Keywords: HIV, broadly neutralizing antibody, neutralizing activity, HIV RNA, natural viral suppressor, elite controller Intro The immune system requires the presence of adequate quantities of antigen in order to elicit an immune response. Despite several studies in HIV-infected individuals, the relationship between HIV-1 antigenic weight and HIV-1 neutralization remains unclear. Several lines of evidence suggest that the antibody response to the HIV-1 envelope lacks durability.1,2 Because of this, we hypothesized that a prolonged but low amount of circulating HIV-1 disease would be necessary to produce and maintain a powerful humoral immune Rolipram response. This study was carried out to examine the relationship between HIV-1 antigenic weight (as reflected by HIV-1 plasma RNA copies/ml) and broad HIV-1 neutralizing antibody activity. Methods Study Individuals Characterization of HIV-1 antigenic weight and neutralizing activity was performed in 120 HIV-infected individuals. These included HIV-1 infected patients with a wide range of viremia, who belonged to one of the following 4 cohorts: 1) HIV-1 Natural Viral Suppressors (NVS) defined as individuals with HIV-1 illness by both Western Blot and proviral DNA, and at least a 2-yr period with 400 HIV-1 RNA copies/ml in the absence of highly active antiretroviral therapy (HAART);3,4 2) Low Viral Weight (LVL) cohort consists of individuals with 500C20,000 HIV-1 RNA copies/ml in the absence of HAART; 3) Medium/High Viral Weight (MHVL) cohort consists of individuals with 20,000 HIV-1 RNA copies/ml in the absence of HAART; and 4) HAART cohort which consists of individuals on their first HAART routine with suppressed viral lots for at least one year. Rolipram Demographic characteristics of these cohorts are given in Table 1. Forty eight NVS, 36 LVL, 18 MHVL, and 18 HAART individuals were tested. This study offers IRB authorization, and all individuals provided educated consent. Table 1 Demographics of the 4 cohorts. HIV-1 Natural Viral Suppressors (NVS) are HIV-infected individuals with HIV-1 RNA 400 copies/ml in the absence of therapy (n=48). thead th valign=”bottom” align=”remaining” rowspan=”1″ colspan=”1″ Cohort /th th valign=”bottom” align=”remaining” rowspan=”1″ colspan=”1″ NVS /th th valign=”bottom” align=”remaining” rowspan=”1″ colspan=”1″ LVL /th th valign=”bottom” align=”remaining” rowspan=”1″ colspan=”1″ MHVL /th th valign=”bottom” align=”remaining” rowspan=”1″ colspan=”1″ HAART /th /thead Age49 (range 29C60)43 (range 24C63)44 (range 22C58)45 (range 23C61)Sex49% M 51% F59% M 41% Rolipram F61% M 39% F78% M 22% FRace100% AA97% AA br / 3% Caucasian89% AA br / 11% Caucasian95% AA br / 5% CaucasianRisk element for IIIV-1 illness59% IDU 43% S35% IDU 65% S52% IDU 48% S23% IDU 77% SMedian years with analysis of HIV-111 (range 2C21)6 (range 0C20)3 (range 1C21)6 (range 1C14)Median of latest HIV-1 viral weight (copies/ml) 50 (range 40C537)1,785 (range 514C19,100)202,000 (range 28,721- 1,000,000) 50Median of latest CD4 count (cells/ul)817 (range 325C1929)632 (range 246C1313)77 (range Rabbit polyclonal to AMN1 3C829)344 (range 134C644) Open in a separate windowpane Low Viral Weight (LVL) are HIV-1 infected patients who are not treated by antiretrovirals whose HIV-1 RNA are 500C20,000 copies/ml (N=36). Medium-High Viral weight (MHVL) are HIV-1 infected persons who are not on antiretroviral therapy whose HIV-1 RNA are 20,000 copies/ml (N=18). The HAART cohort (N=18) is definitely comprised.
Presence of HIV-1 RNA between 102 and 104 copies/ml correlated with quantity of Tier 2 viruses neutralized when compared with those 102 (p
- by globalhealth